Anakinra—An Interleukin-1 Receptor Antagonist for COVID-19

1Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY;

2Transilvania University of Brasov, Romania, Faculty of Medicine, Department of Fundamental Disciplines and Clinical Prevention, Brasov, Romania; and

3Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy Worcester/Manchester, Manchester, NH.

*Address for correspondence: Lorena Dima, MD, PhD, 56 Nicolae Bălcescu Str., 500019 Brasov, Romania. E-mail: [email protected]

The authors have no conflicts of interest to declare.

This article is part of a series evaluating drugs recently approved by the US Food and Drug Administration. The series is coordinated by Timothy Nguyen, PharmD and Kristine Willett, PharmD.

Comments (0)

No login
gif